RedHill Biopharma Ltd. (NASDAQ: RDHL) is an emerging Israeli biopharmaceutical company primarily focused on the development of late clinical-stage small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The company’s current development pipeline is headlined by RHB-105, an oral combination therapy in phase III clinical development for the treatment of Helicobacter pylori infection, and RHB-104, an oral combination therapy in phase III clinical development for the treatment of Crohn’s disease. For more information, visit the company’s website at www.redhillbio.com.